Targeting HDAC and PARP Enhances STING‐Dependent Antitumor Immunity in STING‐Deficient Tumor
Advanced Science · 2025
DOI: 10.1002/advs.202507904 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Chengzhou Mao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Histology, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China. Hauptthemen laut MEDLINE: Membrane Proteins, Histone Deacetylases, Histone Deacetylase Inhibitors, Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Stable Support Project of Shenzhen.
Abstract (Originalsprache)
The stimulator of interferon genes (STING)‐mediated innate immune pathway plays an important role in tumor immunosurveillance. STING deficiency in tumors impairs the interferon response; however, the underlying mechanism remains unclear. Here, it is demonstrated that histone deacetylase (HDAC) suppresses STING expression by reducing H3K9 acetylation at the STING promoter. The combined inhibition of HDAC and poly(ADP‐ribose) polymerase (PARP) induced STING re‐expression and promoted cytosolic DNA accumulation, which further activated the interferon response in STING‐deficient tumors. A bifunctional HDAC and PARP inhibitor displayed potent antitumor immunity by reinducing and activating the STING pathway. Mechanistically, the bifunctional HDAC and PARP inhibitor induced “BRCAness,” thereby restoring synthetic lethality, reactivating STING expression, and promoting the infiltration and activation of T cells and dendritic cells in the tumor microenvironment. Notably, STING depletion reversed the antitumor effect. Moreover, dual inhibition of HDAC and PARP significantly enhanced the antitumor immune response to immune checkpoint blockade by inducing adaptive immune memory. These findings underscore dual HDAC and PARP inhibition as a promising therapeutic strategy for overcoming the STING pathway deficiency and augmenting antitumor immunity in cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy and Histology, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China.
- Guangdong Provincial Key Laboratory of Chinese Medicine Ingredients and Gut Microbiomics, School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China.
- Present address: Department of Pharmacy, The Second Hospital of Longyan, Longyan, 364099, China.
- Institute of Biomedical Health Technology and Engineering, Shenzhen Bay Laboratory, Shenzhen, 518132, China.
- State Key Laboratory of Chemical Oncogenomics, Tsinghua Shenzhen International Graduate School, Shenzhen, 518055, China.
ORCID-Profile: Bizhu Chu
Förderung
- National Natural Science Foundation of China
- Stable Support Project of Shenzhen
Zitieren
APA
Mao, C., Fan, W., Liu, J., Yang, F., Li, W., Li, L., Shi, Z., Li, Q., Yuan, Z., Jiang, Y., & Chu, B. (2025). Targeting HDAC and PARP Enhances STING‐Dependent Antitumor Immunity in STING‐Deficient Tumor. Advanced Science. https://doi.org/10.1002/advs.202507904
Vancouver
Mao C, Fan W, Liu J, Yang F, Li W, Li L, et al. Targeting HDAC and PARP Enhances STING‐Dependent Antitumor Immunity in STING‐Deficient Tumor. Advanced Science. 2025. doi:10.1002/advs.202507904
BibTeX
@article{Mao2025,
author = {Mao, Chengzhou and Fan, Weiwen and Liu, Jiaqi and Yang, Fangzhou and Li, Wenkai and Li, Lulu and Shi, Zhichao and Li, Qinyuan and Yuan, Zigao and Jiang, Yuyang and Chu, Bizhu},
title = {Targeting HDAC and PARP Enhances STING‐Dependent Antitumor Immunity in STING‐Deficient Tumor},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202507904}
}
EUVIMED